A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

NCT05319353 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Cytomegalovirus (CMV)

Interventions

DRUG: Maribavir

Sponsor

Takeda

Collaborators

[object Object]